DokumenMolMeddiunggah oleh
social_molmed- DokumenMolMed Rafforzamento Del Governo Societariodiunggah olehsocial_molmed
- DokumenMolMed NGR-hTNF mesothelioma, oral presentation at ASCO 2015diunggah olehsocial_molmed
- DokumenMolMed NGRhTNF ASCO New Data Show Significantly Extended Survivaldiunggah olehsocial_molmed
- DokumenNuovi Dati Presentati Ad ASCO Su NGR-hTNF Incremento Sopravvivenza Globalediunggah olehsocial_molmed
- DokumenMolMed TK ASCO New Data From the Pivotal Phase III Randomized Trial TK008diunggah olehsocial_molmed
- DokumenMolMed TK ASCO nuovi dati dello studio randomizzato registrativo Fase III TK008diunggah olehsocial_molmed
- DokumenMolMed reports top line results of NGR-hTNF in the phase III trial in malignant pleural mesotheliomadiunggah olehsocial_molmed
- DokumenMolMed annuncia i risultati di NGR-hTNF nello studio di Fase III nel mesotelioma pleurico malignodiunggah olehsocial_molmed
- DokumenTK submission for Conditional Approval validated by EMAdiunggah olehsocial_molmed
- DokumenL'EMA ha validato la sottomissione della domanda di Conditional Approval per TKdiunggah olehsocial_molmed
- DokumenMolMed TK therapy submitted for Conditional Marketing Authorisation in EUdiunggah olehsocial_molmed
- DokumenMolMed deposita domanda di Conditional Marketing Authorisation in Europa per la terapia TKdiunggah olehsocial_molmed
- DokumenMolMed Approved The Interim Financial Report At 30 September 2013diunggah olehsocial_molmed
- DokumenMolMed Approvato Resoconto Intermedio Gestione 30 Settembre 2013diunggah olehsocial_molmed
- DokumenMolMed expands in the United States the Phase III trial of TK for the treatment of high-risk leukaemiadiunggah olehsocial_molmed
- DokumenFase III TK Stati Unitidiunggah olehsocial_molmed
- DokumenMolMed NGR-hTNFdiunggah olehsocial_molmed
- DokumenLuigi Roth Presidente Terna Eletto Presidente Gruppo Lombardo Federazione Nazionale Cavalieri Del Lavorodiunggah olehsocial_molmed
- DokumenEuropean Cancer Congress, MolMed on efficacy of drug NGR-hTNFdiunggah olehsocial_molmed
- DokumenEuropean Cancer Congress MolMed Nuovi Dati Su NGR hTNF Aumento Sopravvivenza Nei Sarcomidiunggah olehsocial_molmed
- DokumenEuropean Cancer Congress MolMed Su Farmaco Sperimentale NGR-hTNFdiunggah olehsocial_molmed
- DokumenMolMed Outcome of Shareholders' Meeting and Meeting Ff Board of Directorsdiunggah olehsocial_molmed
- DokumenMolMed Assemblea Azionistidiunggah olehsocial_molmed
- DokumenMolMed official notification from the European Patent Office for NGR-hTNFdiunggah olehsocial_molmed
- DokumenUfficio Europeo Brevetti MolMed Nuovo Brevetto Per Biofarmaco Antitumorale NGR-hTNFdiunggah olehsocial_molmed
- DokumenMolMed NGR-hTNFdiunggah olehsocial_molmed
- DokumenIl Consiglio Di Amministrazione Di MolMed Approva La Relazione Finanziaria Semestrale Al 30 Giugno 2013diunggah olehsocial_molmed
- DokumenMolMed TKdiunggah olehsocial_molmed
- DokumenMolMed ASCO 2013diunggah olehsocial_molmed
- DokumenMolMed TK ASCO Sicurezza e sopravvivenza a lungo termine con TKdiunggah olehsocial_molmed
- DokumenMolMed NGR-hTNFdiunggah olehsocial_molmed
- DokumenMolMed NGR-hTNF four studies accepted for presentation at ASCO 2013diunggah olehsocial_molmed
- DokumenMolMed TKdiunggah olehsocial_molmed
- DokumenAggiornamento sviluppo clinico dei prodotti MolMeddiunggah olehsocial_molmed
- DokumenCdA MolMed approva resoconto intermedio di gestione al 31 marzo 2013diunggah olehsocial_molmed
- DokumenMolMeddiunggah olehsocial_molmed
- DokumenMolMeddiunggah olehsocial_molmed
- DokumenMolMeddiunggah olehsocial_molmed
- DokumenMolMeddiunggah olehsocial_molmed
- DokumenMolMed TKdiunggah olehsocial_molmed
- DokumenMolmed (TK)diunggah olehsocial_molmed
- DokumenMolMed TKdiunggah olehsocial_molmed
- DokumenMolMeddiunggah olehsocial_molmed
- DokumenMolMed TK BMTdiunggah olehsocial_molmed
- DokumenMolMeddiunggah olehsocial_molmed
- DokumenMolMed NGR-hTNFdiunggah olehsocial_molmed
- DokumenMesotelioma recidivantediunggah olehsocial_molmed
- DokumenMolmed TK ASHdiunggah olehsocial_molmed
